Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans.
B cell memory
CITE-seq
alternative B cell lineage
atypical B cells
malaria
single cell RNA-seq
sporozoite
vaccination
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
09 02 2021
09 02 2021
Historique:
received:
28
04
2020
revised:
19
11
2020
accepted:
30
12
2020
entrez:
10
2
2021
pubmed:
11
2
2021
medline:
18
1
2022
Statut:
ppublish
Résumé
The diversity of circulating human B cells is unknown. We use single-cell RNA sequencing (RNA-seq) to examine the diversity of both antigen-specific and total B cells in healthy subjects and malaria-exposed individuals. This reveals two B cell lineages: a classical lineage of activated and resting memory B cells and an alternative lineage, which includes previously described atypical B cells. Although atypical B cells have previously been associated with disease states, the alternative lineage is common in healthy controls, as well as malaria-exposed individuals. We further track Plasmodium-specific B cells after malaria vaccination in naive volunteers. We find that alternative lineage cells are primed after the initial immunization and respond to booster doses. However, alternative lineage cells develop an atypical phenotype with repeated boosts. The data highlight that atypical cells are part of a wider alternative lineage of B cells that are a normal component of healthy immune responses.
Identifiants
pubmed: 33567273
pii: S2211-1247(20)31673-9
doi: 10.1016/j.celrep.2020.108684
pmc: PMC7873835
pii:
doi:
Substances chimiques
Antibodies, Protozoan
0
Malaria Vaccines
0
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108684Subventions
Organisme : EPA
ID : EP-C-15-003
Pays : United States
Organisme : NIAID NIH HHS
ID : R44 AI055229
Pays : United States
Organisme : NIAID NIH HHS
ID : R44 AI058375
Pays : United States
Organisme : NIAID NIH HHS
ID : R44 AI058499
Pays : United States
Organisme : Medical Research Council
ID : MR/P020321/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests S.C., N.K., B.K.L.S., and S.L.H. are salaried employees of Sanaria, the developer and owner of PfSPZ Vaccine and the investigational new drug (IND) application sponsor of the clinical trials. S.L.H. and B.K.L.S. have a financial interest in Sanaria. All other authors declare no competing interests.
Références
J Exp Med. 1998 Nov 2;188(9):1691-703
pubmed: 9802981
PLoS Pathog. 2017 Sep 27;13(9):e1006576
pubmed: 28953967
Sci Transl Med. 2018 Feb 14;10(428):
pubmed: 29444980
J Immunol. 2009 Aug 1;183(3):2176-82
pubmed: 19592645
Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2711-2716
pubmed: 28223498
Nat Methods. 2017 Sep;14(9):865-868
pubmed: 28759029
PLoS Pathog. 2015 May 19;11(5):e1004894
pubmed: 25993340
Elife. 2019 Nov 12;8:
pubmed: 31713516
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Immunity. 2018 Oct 16;49(4):725-739.e6
pubmed: 30314758
Clin Exp Immunol. 2002 Dec;130(3):370-8
pubmed: 12452825
J Immunol. 2007 May 15;178(10):6624-33
pubmed: 17475894
J Immunol. 2005 Apr 1;174(7):4034-42
pubmed: 15778361
J Immunol. 2003 Jan 15;170(2):686-94
pubmed: 12517929
Nat Protoc. 2014 Jan;9(1):171-81
pubmed: 24385147
Sci Immunol. 2018 Feb 16;3(20):
pubmed: 29453292
Blood. 2011 May 19;117(20):5425-37
pubmed: 21421840
PLoS Pathog. 2010 May 20;6(5):e1000912
pubmed: 20502681
Elife. 2018 Nov 02;7:
pubmed: 30387712
J Immunol. 2009 Jan 15;182(2):890-901
pubmed: 19124732
Sci Immunol. 2017 Jan 27;2(7):
pubmed: 28783670
Blood. 1997 Feb 15;89(4):1288-98
pubmed: 9028952
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):E3216-24
pubmed: 23922396
Immunity. 2019 Aug 20;51(2):398-410.e5
pubmed: 31350180
Eur J Immunol. 2020 Aug;50(8):1187-1194
pubmed: 32222961
Elife. 2015 May 08;4:
pubmed: 25955968
J Immunol. 2013 Feb 1;190(3):1038-47
pubmed: 23264654
Science. 2011 Mar 4;331(6021):1203-7
pubmed: 21310965
Blood. 2010 Jun 17;115(24):5026-36
pubmed: 20231422
Immunity. 2020 May 19;52(5):842-855.e6
pubmed: 32353250
J Exp Med. 2013 Feb 11;210(2):389-99
pubmed: 23319701
Immunity. 2016 Aug 16;45(2):402-14
pubmed: 27473412
Bioinformatics. 2018 Aug 15;34(16):2846-2847
pubmed: 29659703
Cell Rep. 2019 Apr 30;27(5):1446-1460.e4
pubmed: 31042472
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
Immunity. 2002 Jul;17(1):51-62
pubmed: 12150891
J Exp Med. 2008 Aug 4;205(8):1797-805
pubmed: 18625747
Nat Med. 2016 Jun;22(6):614-23
pubmed: 27158907
Nat Immunol. 2006 Jul;7(7):773-82
pubmed: 16767092
J Exp Med. 2005 Sep 19;202(6):783-91
pubmed: 16157685
JCI Insight. 2017 Apr 20;2(8):
pubmed: 28422752
Immunity. 2020 Jul 14;53(1):217-232.e5
pubmed: 32668225
Nature. 2001 Jul 19;412(6844):300-7
pubmed: 11460154
J Immunol. 2006 Sep 15;177(6):3728-36
pubmed: 16951333
Cell Host Microbe. 2020 Oct 7;28(4):572-585.e7
pubmed: 32697938
Nat Immunol. 2016 Oct;17(10):1226-34
pubmed: 27525369